Advanced search
Publication Cover
Hematology Volume 28, 2023 - Issue 1
Submit an article Journal homepage
979
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Recurrence of acute chest syndrome post stopping Crizanlizumab, the dilemma of stopping vs continuation in patient with sickle cell disease: case report

Mohammad S. Afanaa Hematology Section, Department of Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarCorrespondence[email protected]
View further author information
,
Mohammad Abu-Tineha Hematology Section, Department of Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarView further author information
,
Awni Alshurafaa Hematology Section, Department of Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarView further author information
,
Ahmed K. Yasinb Department of Internal Medicine, Hamad Medical Corporation, Doha, QatarView further author information
,
Khalid Ahmeda Hematology Section, Department of Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarView further author information
,
Mohammed Abdulgayooma Hematology Section, Department of Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarView further author information
&
Mohamed A. Yassina Hematology Section, Department of Medical Oncology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarView further author information
 show all
Article: 2229115 | Received 26 Mar 2023, Accepted 20 Jun 2023, Published online: 31 Jul 2023

References

  • Yousef AA, Shash HA, Almajid AN, et al. Predictors of recurrent acute chest syndrome in pediatric sickle cell disease: a retrospective case-control study. Children. 2022 Jun;9(6):894. doi:10.3390/children9060894
  • Kavanagh PL, Fasipe TA, Wun T. Sickle cell disease: a review. JAMA. 2022 Jul;328(1):57–68. doi:10.1001/jama.2022.10233
  • Weaver SB, Rungkitwattanakul D, Singh D. Contemporary management and prevention of vaso-occlusive crises (VOCs) in adults with sickle cell disease. J Pharm Pract. 2023 Feb;36(1):139–148. doi:10.1177/08971900211026644
  • Ata F, Rahhal A, Malkawi L, et al. Genotypic and phenotypic composition of sickle cell disease in the arab population-A systematic review. Pharmgenom Pers Med. 2023 Dec: 133–144. doi:10.2147/PGPM.S391394
  • Okar L, Rezek M, Gameil A, et al. Severe hemolysis and vaso-occlusive crisis due to COVID-19 infection in a sickle cell disease patient improved after red blood cell exchange. Clin Case Rep. 2021 Apr;9(4):2117–2121. doi:10.1002/ccr3.3960
  • Han J, Saraf SL, Gordeuk VR. Systematic review of crizanlizumab: a new parenteral option to reduce vaso-occlusive pain crises in patients with sickle cell disease. Pharmacoth: J. Human Pharma Drug Therap. 2020 Jun;40(6):535–543. doi:10.1002/phar.2409
  • Adel AA, Abushanab D, Hamad A, et al. L-glutamine and crizanlizumab for adults with sickle cell disease (SCD) in Qatar: a cost effectiveness analysis. Blood. 2021 Nov;138:4945. doi:10.1182/blood-2021-144636
  • Delicou S, Aggeli K, Magganas K, et al. Acute chest syndrome in sickle cell disease: clinical presentation and outcomes. The experience of a single thalassemia and sickle cell unit in a university hospital. Hemoglobin. 2021 Sep;45(5):303–308. doi:10.1080/03630269.2021.2006690
  • Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med. 2008 Nov0;359(21):2254–2265. doi:10.1056/NEJMra0804411
  • Stevens DL, Hix M, Gildon BL. Crizanlizumab for the prevention of vaso-occlusive pain crises in sickle cell disease. J Pharm Technol. 2021 Aug;37(4):209–215. doi:10.1177/87551225211008460
  • Alshurafa A, Yassin MA. Short-and long-term follow-up and additional benefits in a sickle cell disease patient experienced severe crizanlizumab infusion-related vaso-occlusive crisis: a case report. Front Med (Lausanne). 2022;9. doi:10.3389/fmed.2022.1048571
  • Karki NR, Kutlar A. P-selectin blockade in the treatment of painful vaso-occlusive crises in sickle cell disease: a spotlight on crizanlizumab. J Pain Res. 2021;14:849–856. doi:10.2147/JPR.S278285
  • Rozi W, Rahhal A, Ali EA, et al. Direct oral anticoagulants in sickle cell disease: a systematic review and meta-analysis. Blood Adv. 2022 Sep 13;6(17):5061–5066. doi10.2147/JPR.S27828
  • Yassin M, Soliman A, De Sanctis V, et al. Liver iron content (LIC) in adults with sickle cell disease (SCD): correlation with serum ferritin and liver enzymes concentrations in trasfusion dependent (TD-SCD) and non-transfusion dependent (NT-SCD) patients. Mediterr J Hematol Infect Dis. 2017;9(1). doi:10.4084/MJHID.2017.037
  • Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376:429–439. doi:10.1056/NEJMoa1611770

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.